SCHEMBL6320276

SCHEMBL6320276

Cc1ccc(S(=O)(=O)NC(=O)c2ccc3[nH]c(C)c(Cc4ccc(-c5ccco5)cc4Cl)c3c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.41
MAPT P10636 3/20 0.40
MCL1 Q07820 5/20 0.39
KAT6A Q92794 3/20 0.39
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
MGAM O43451 2/20 0.37
GAA P10253 2/20 0.37
SI P14410 2/20 0.37
MGAM2 Q2M2H8 2/20 0.37
BCL2L1 Q07817 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5881759 0.88 PTGS2 (0.46) PTGS2MAPTMCL1HDAC3HDAC4
SCHEMBL5881768 0.85 FLT1 (0.51) PTGS2MAPTHDAC3HDAC4HDAC1
SCHEMBL6317321 0.85 PPARG (0.41) PTGS2MAPTMCL1BCL2L1MEN1
SCHEMBL6135028 0.84 MAPT (0.42) PTGS2MAPTMCL1KAT6AHDAC3
SCHEMBL5881622 0.83 MAPT (0.46) PTGS2MAPTMCL1KAT6AHDAC3
SCHEMBL6321295 0.83 PTGS2 (0.43) PTGS2MAPTHDAC3HDAC4HDAC1
SCHEMBL6319512 0.83 MGAM (0.43) PTGS2MAPTHDAC3HDAC4HDAC1
SCHEMBL6325375 0.83 PTPN5 (0.48) PTGS2MAPTGAAMEN1KMT2A
SCHEMBL6319227 0.83 MEN1 (0.44) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5881771 0.82 FLT1 (0.51) PTGS2MAPTMCL1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US claimed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP claimed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
US-6852731-B2 Antiviral compounds PFIZER (US) 2005-02-08 US disclosed
US-20040242884-A1 ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY 2004-12-02 US disclosed
EP-1472260-A2 THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2004-11-03 EP disclosed
WO-2003059878-A2 THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242884-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, IRF3, IFNAR1 PTGS2 2491/4885MAPT 3255/4885MCL1 1104/4885
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A PTGS2 2111/4885MAPT 3941/4885MCL1 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.